- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Medicus Pharma Ltd. - S-1, General form for registration of securities | - | SEC Filings | ||
| Mo | Medicus Pharma: Aktie springt nach Antrag auf beschleunigte FDA-Zulassung | 3 | Investing.com Deutsch | ||
| Mo | Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 283 | ACCESS Newswire | SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access... ► Artikel lesen | |
| 14.11. | Medicus Pharma Ltd. reports Q3 results | 1 | Seeking Alpha | ||
| 14.11. | Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights | 315 | ACCESS Newswire | Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire... ► Artikel lesen | |
| 14.11. | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.11. | Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study To Non-Invasively Treat Basal Cell Carcinoma of the Skin | 258 | ACCESS Newswire | THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire /... ► Artikel lesen | |
| 29.10. | Medicus Pharma recruits first patient in cancer patch trial | 2 | PMLiVE | ||
| 29.10. | Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT in Patients with Gorlin Syndrome | 143 | GlobeNewswire (Europe) | PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 22.10. | Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 236 | ACCESS Newswire | CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the... ► Artikel lesen | |
| 17.10. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets | 262 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.The NASDAQ-listed... ► Artikel lesen | |
| 13.10. | Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 | 230 | ACCESS Newswire | EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX)... ► Artikel lesen | |
| 07.10. | Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE | 245 | ACCESS Newswire | EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7... ► Artikel lesen | |
| 29.09. | Medicus Pharma Ltd. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.09. | Medicus Pharma gets FDA nod for 505(b)(2) pathway in skin cancer treatment | 1 | Investing.com | ||
| 29.09. | Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration Type C Meeting Supporting the Development of Skinject | 201 | ACCESS Newswire | The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA)... ► Artikel lesen | |
| 24.09. | Medicus Pharma Ltd. To Present at Brookline Capital Markets | 269 | ACCESS Newswire | The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix... ► Artikel lesen | |
| 18.09. | Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing | 283 | ACCESS Newswire | The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV... ► Artikel lesen | |
| 12.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,710 | -0,14 % | Aktien New York Ausblick: Weitere Stabilisierung vor Daten und Nvidia-Zahlen | NEW YORK (dpa-AFX) - Für die US-Börsen zeichnet sich am Montag eine weitere Stabilisierung ab. Vor der im weiteren Wochenverlauf erwarteten, verspäteten Veröffentlichung wichtiger US-Konjunkturdaten... ► Artikel lesen | |
| GILEAD SCIENCES | 110,92 | +0,78 % | SA analyst upgrades/downgrades: GILD, UBER, FROG, JACK | ||
| ELI LILLY | 920,00 | -0,05 % | Eli-Lilly-Aktie kratzt am Allzeithoch -Papier setzt Aufwärtsserie fort | Die Eli-Lilly-Aktie zählt zu den attraktivsten Papieren am Börsenmarkt und zeigt seit Jahren eine beeindruckende Aufwärtsrallye mit nur wenigen Rücksetzern. Die langanhaltende Performance verdeutlicht... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 376,15 | +1,48 % | VERTEX PHARMACEUTICALS INC stürzt ab - Alarmstufe Rot! | ||
| EYEPOINT PHARMACEUTICALS | 11,825 | -0,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration | - No changes in protocol recommended for LUGANO and LUCIA clinical trials - - Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU - - On track... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,800 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 175,00 | +1,16 % | Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year | ||
| OPKO HEALTH | 1,143 | -0,63 % | JPMorgan initiates Opko Health stock with Neutral rating | ||
| JAZZ PHARMACEUTICALS | 153,55 | -0,03 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference | DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company... ► Artikel lesen | |
| ROYALTY PHARMA | 33,740 | -0,18 % | Dividendenbekanntmachungen (14.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,73 USD 0,6273 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2492 EUR ALBEMARLE CORPORATION PREF A US0126532003 0... ► Artikel lesen | |
| UNITED THERAPEUTICS | 412,70 | +0,15 % | United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base | ||
| CATALYST PHARMACEUTICALS | 20,260 | +0,25 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 | ||
| BRIDGEBIO PHARMA | 60,40 | +2,20 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| TG THERAPEUTICS | 27,990 | +0,88 % | TG Therapeutics, Inc.: TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies | ||
| AVADEL PHARMACEUTICALS | 19,900 | -0,50 % | Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc | DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
17-Nov-2025 / 17:25 GMT/BST
... ► Artikel lesen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,080 (+3,90 %) liegt der Kurs bei 2,130 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.